全文获取类型
收费全文 | 1332篇 |
免费 | 111篇 |
国内免费 | 69篇 |
出版年
2024年 | 4篇 |
2023年 | 43篇 |
2022年 | 58篇 |
2021年 | 93篇 |
2020年 | 77篇 |
2019年 | 92篇 |
2018年 | 77篇 |
2017年 | 66篇 |
2016年 | 77篇 |
2015年 | 81篇 |
2014年 | 104篇 |
2013年 | 152篇 |
2012年 | 62篇 |
2011年 | 84篇 |
2010年 | 53篇 |
2009年 | 41篇 |
2008年 | 29篇 |
2007年 | 49篇 |
2006年 | 39篇 |
2005年 | 35篇 |
2004年 | 21篇 |
2003年 | 24篇 |
2002年 | 18篇 |
2001年 | 26篇 |
2000年 | 17篇 |
1999年 | 10篇 |
1998年 | 7篇 |
1997年 | 11篇 |
1996年 | 9篇 |
1995年 | 10篇 |
1994年 | 5篇 |
1993年 | 6篇 |
1992年 | 1篇 |
1991年 | 6篇 |
1990年 | 1篇 |
1989年 | 5篇 |
1988年 | 6篇 |
1986年 | 1篇 |
1985年 | 5篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1980年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
排序方式: 共有1512条查询结果,搜索用时 15 毫秒
221.
222.
223.
Sophie Dupuis-Girod Alexis Ambrun Evelyne Decullier Géraldine Samson Adeline Roux Anne-Emmanuelle Fargeton Catherine Rioufol Verane Schwiertz Fran?ois Disant Fran?ois Chapuis Yves Donazzolo Gilles Paintaud Patrick Edery Frederic Faure 《MABS-AUSTIN》2014,6(3):793-798
Background: Hereditary hemorrhagic telangiectasia (HHT) is a dominantly inherited genetic vascular disorder in which epistaxis is the most frequent manifestation, responsible for high morbidity. Management of this symptom has no standard, and local treatments are often aggressive. Their efficacy is variable and has not been proven. Anti-angiogenic drugs, such as bevacizumab, are a new treatment strategy. Its systemic administration in patients with HHT improves liver damage-related symptoms and epistaxis. To limit the systemic adverse effects of bevacizumab and to ease administration, a local administration seems suitable. Primary objective: To evaluate the tolerance of increasing doses of bevacizumab administered as a nasal spray in patients with HHT-related epistaxis. Secondary objectives were to study the bioavailability and efficacy of bevacizumab against epistaxis when given as a nasal spray. Methodology: Phase 1, randomized, double-blind, placebo-controlled, monocentric study performed sequentially (dose escalation) on 5 groups of 8 patients. Each group was made up of 6 verum and 2 placebos. Five increasing doses of bevacizumab nasal spray (25 mg/mL) were evaluated: 12.5, 25, 50, 75 and 100 mg. Results: A total of 40 patients were included between October 2011 and October 2012. Bevacizumab nasal spray was well tolerated in all patients and the drug was not detected in their serum. No dose limiting toxicity was observed. No efficacy was observed at any dose in this study. Conclusion: Based on these results, bevacizumab nasal spray is a safe treatment of epistaxis in HHT. However, a randomized Phase 2 study is needed to determine its efficacy. Trial Registration: ClinicalTrials.gov Identifier # NCT01507480相似文献
224.
The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any independent verification that the observed effects in vitro may be valid in a clinical setting, and that the drug could potentially affect patient survival in vivo is of paramount importance. Despite considerable recent efforts in computational drug repositioning, none of the studies have considered patient survival information in modelling the potential of existing/new drugs in the management of cancer. Therefore, we have developed DRUGSURV; this is the first computational tool to estimate the potential effects of a drug using patient survival information derived from clinical cancer expression data sets. DRUGSURV provides statistical evidence that a drug can affect survival outcome in particular clinical conditions to justify further investigation of the drug anticancer potential and to guide clinical trial design. DRUGSURV covers both approved drugs (∼1700) as well as experimental drugs (∼5000) and is freely available at http://www.bioprofiling.de/drugsurv. 相似文献
225.
226.
人体内一种不容忽视的氨基酸--牛磺酸 总被引:25,自引:0,他引:25
牛磺酸是人体内的一种非必需氨基酸,具有广泛的生理功能,其作用可与水分子的作用相提并论。本文介绍了牛磺酸的分布与代谢、生物学效应、在临床上的应用及人体的需要程度。 相似文献
227.
228.
Yueshui Zhao Sipeng Guo Jian Deng Jing Shen Fukuan Du Xu Wu Yu Chen Mingxing Li Meijuan Chen Xiaobing Li Wanping Li Li Gu Yuhong Sun Qinglian Wen Jing Li Zhangang Xiao 《International journal of biological sciences》2022,18(9):3845
Non-small cell lung cancer (NSCLC) is the leading cause of death by cancer worldwide. Despite developments in therapeutic approaches for the past few decades, the 5-year survival rate of patients with NSCLC remains low. NSCLC tumor is a complex, heterogeneous microenvironment, comprising blood vessels, cancer cells, immune cells, and stroma cells. Vascular endothelial growth factors (VEGFs) are a major mediator to induce tumor microvasculature and are associated with the progression, recurrence, and metastasis of NSCLC. Current treatment medicines targeting VEGF/VEGF receptor (VEGFR) pathway, including neutralizing antibodies to VEGF or VEGFR and receptor tyrosine kinase inhibitors, have shown good treatment efficacy in patients with NSCLC. VEGF is not only an important angiogenic factor but also an immunomodulator of tumor microenvironment (TME). VEGFs can suppress antigen presentation, stimulate activity of regulatory T (Treg) cells, and tumor-associated macrophages, which in turn promote an immune suppressive microenvironment in NSCLC. The present review focuses on the angiogenic and non-angiogenic functions of VEGF in NSCLC, especially the interaction between VEGF and the cellular components of the TME. Additionally, we discuss recent preclinical and clinical studies to explore VEGF/VEGFR-targeted compounds and immunotherapy as novel approaches targeting the TME for the treatment of NSCLC. 相似文献
229.
Weifeng He Yuan Gao Jing Zhou Yi Shi Dajing Xia Han-Ming Shen 《International journal of biological sciences》2022,18(12):4690
There is increasing amount of evidence indicating the close interplays between the replication cycle of SARS-CoV-2 and the autophagy-lysosome pathway in the host cells. While autophagy machinery is known to either assist or inhibit the viral replication process, the reciprocal effects of the SARS-CoV-2 on the autophagy-lysosome pathway have also been increasingly appreciated. More importantly, despite the disappointing results from the clinical trials of chloroquine and hydroxychloroquine in treatment of COVID-19, there is still ongoing effort in discovering new therapeutics targeting the autophagy-lysosome pathway. In this review, we provide an update-to-date summary of the interplays between the autophagy-lysosome pathway in the host cells and the pathogen SARS-CoV-2 at the molecular level, to highlight the prognostic value of autophagy markers in COVID-19 patients and to discuss the potential of developing novel therapeutic strategies for COVID-19 by targeting the autophagy-lysosome pathway. Thus, understanding the nature of such interactions between SARS-CoV-2 and the autophagy-lysosome pathway in the host cells is expected to provide novel strategies in battling against this global pandemic. 相似文献
230.
近年来数字PCR技术作为第三代PCR技术迅猛发展,已被应用于无创产前筛查、病毒核酸检测及肿瘤液体活检等领域。以中国生物医学文献数据库、PubMed医学文献检索服务系统及Incopat专利数据库收录的与“数字PCR技术临床应用”相关的中英文论文和专利文献为数据源,利用计量学方法分析了数字PCR临床应用现状与技术热点趋势,明确该技术的主要研究机构包括美国弗雷德-哈钦森肿瘤研究中心、哈佛医学院丹娜法伯癌症研究所和Bio-Rad公司等。中文文献发表机构中检验检疫部门和疾控中心占比较高。国内外数字PCR技术研究主要聚焦于肿瘤伴随诊断、病毒检测和基因表达分析等方面。中国数字PCR技术研究热情较高,专利申请已展现出国际领先趋势。 相似文献